Because the available literature indicates that isocitrate dehydrogenase (IDH) glioma mutants showed a better prognosis compared to IDH-wildtype glioma patients at different WHO grades [20,21], we also analyzed Nogo-A, MAG, and OMgp levels depending on the IDH1 gene mutation in the astrocytic brain tumour subgroup. The gene discussed is IDH3A; the disease is central nervous system cancer.